• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

4

CATEGORIES

  • 15
  • 6
  • 5
  • 3
  • 1
  • 1
  • 1

PRICE

5
5
8
30

PUBLISHED

0
1
9
30

PRODUCT TYPE

30

Search "Novartis AG: PharmaVitae Profile" returned 30 results.

PRODUCT TITLE

Atherosclerosis - Pipeline Review, H2 2013

Atherosclerosis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Atherosclerosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

August 2013
FROM

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2013

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2013', provides an...

August 2013
FROM

Kidney Disease - Pipeline Review, H2 2013

Kidney Disease - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Kidney Disease - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

August 2013
FROM
Renal Failure - Pipeline Review, H1 2013 Renal Failure - Pipeline Review, H1 2013 - Product Thumbnail Image

Renal Failure - Pipeline Review, H1 2013

Renal Failure – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Renal Failure - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

March 2013
FROM
Big Pharma M&A Analysis to 2012 - Surveying the Growth Rate Landscape Big Pharma M&A Analysis to 2012 - Surveying the Growth Rate Landscape - Product Thumbnail Image

Big Pharma M&A Analysis to 2012 - Surveying the Growth Rate Landscape

With sales growth rates expected to fall below their historic levels, Big Pharma must act to bolster its performance out to 2012 if it is to maintain the investment communitys valuation of its stocks....

August 2008
FROM
Kidney Disease - Pipeline Review, H1 2013 Kidney Disease - Pipeline Review, H1 2013 - Product Thumbnail Image

Kidney Disease - Pipeline Review, H1 2013

Kidney Disease – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Kidney Disease - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

March 2013
FROM

Post-Operative Pain - Pipeline Review, H1 2013

Post-Operative Pain – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Post-Operative Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

June 2013
FROM
Renal Failure - Pipeline Review, H2 2012 Renal Failure - Pipeline Review, H2 2012 - Product Thumbnail Image

Renal Failure - Pipeline Review, H2 2012

Renal Failure – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Renal Failure - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides...

September 2012
FROM

Alzheimer's Disease - Pipeline Review, H2 2013

'Alzheimer's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Alzheimer's Disease,...

August 2013
FROM
Arteriosclerosis - Pipeline Review, H2 2012 Arteriosclerosis - Pipeline Review, H2 2012 - Product Thumbnail Image

Arteriosclerosis - Pipeline Review, H2 2012

Arteriosclerosis – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Arteriosclerosis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report...

December 2012
FROM
Neurodegenerative Diseases - Pipeline Review, H2 2012 Neurodegenerative Diseases - Pipeline Review, H2 2012 - Product Thumbnail Image

Neurodegenerative Diseases - Pipeline Review, H2 2012

Neurodegenerative Diseases – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Neurodegenerative Diseases - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic...

September 2012
FROM
Treatment Algorithms: Schizophrenia – New Antipsychotic Launches Underwhelm Treatment Algorithms: Schizophrenia – New Antipsychotic Launches Underwhelm - Product Thumbnail Image

Treatment Algorithms: Schizophrenia – New Antipsychotic Launches Underwhelm

Analysis of current treatment dynamics in schizophrenia The report assesses patient diagnosis rates and uptake rates of approved treatments across the seven major markets using Datamonitor’s primary...

May 2012
FROM
Product Profiles: Pipeline Antibacterials - Gram-negative combination antibiotics show promise in MRSA-focused pipeline Product Profiles: Pipeline Antibacterials - Gram-negative combination antibiotics show promise in MRSA-focused pipeline - Product Thumbnail Image

Product Profiles: Pipeline Antibacterials - Gram-negative combination antibiotics show promise in MRSA-focused pipeline

The majority of the drugs in the late stage of the pipeline are being developed to target Gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). Progress has been slow,...

January 2012
FROM

Inflammation - Pipeline Review, H1 2013

Inflammation – Pipeline Review, H1 2013 Summary 'Inflammation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic...

June 2013
FROM
Atherosclerosis - Pipeline Review, H1 2013 Atherosclerosis - Pipeline Review, H1 2013 - Product Thumbnail Image

Atherosclerosis - Pipeline Review, H1 2013

Atherosclerosis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Atherosclerosis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

February 2013
FROM
Big Pharma Mega-Mergers 1995-2014 Big Pharma Mega-Mergers 1995-2014 - Product Thumbnail Image

Big Pharma Mega-Mergers 1995-2014

Mega-mergers (defined here as M&A events with deal sizes >$5bn) have been a long-term strategic feature of the pharmaceutical industry and have played a key role in shaping the structure and composition...

December 2009
FROM
Alzheimer's Disease - Pipeline Review, H2 2012 Alzheimer's Disease - Pipeline Review, H2 2012 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H2 2012

Alzheimer's Disease – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Alzheimer's Disease - Pipeline Review, H2 2012', provides an overview of the Alzheimer's Disease therapeutic pipeline....

August 2012
FROM
Neurodegenerative Drugs - Global Strategic Business Report Neurodegenerative Drugs - Global Strategic Business Report - Product Thumbnail Image

Neurodegenerative Drugs - Global Strategic Business Report

This report analyzes the worldwide markets for Neurodegenerative Drugs in US$ Million by the following disease types: Alzheimers Disease, Parkinsons Disease, Multiple Sclerosis, Amyotrophic Lateral...

April 2010
FROM
Cardiovascular Disease: Recent Drug Advances and Impending Risks Cardiovascular Disease: Recent Drug Advances and Impending Risks - Product Thumbnail Image

Cardiovascular Disease: Recent Drug Advances and Impending Risks

There are nearly 300 medicines in clinical development to treat cardiovascular disease This new research report examines in detail the key areas of the cardiovascular (CV) market, gathering inside opinion...

June 2013
Product Profiles: Depression - Next generation vies for second-line patients Product Profiles: Depression - Next generation vies for second-line patients - Product Thumbnail Image

Product Profiles: Depression - Next generation vies for second-line patients

Patents for the current market-leading depression brands are due to expire in the major markets between 2012 and 2015, by which time competition in the market will be at its fiercest. In order to flourish...

January 2012
FROM
Loading Indicator